Synchronous bladder and prostate cancer specimens obtained from radical cystoprostatectomy: A single‑center retrospective analysis.
incidental prostate cancer
prostate sparing surgery
radical cystoprostatectomy
Journal
Experimental and therapeutic medicine
ISSN: 1792-1015
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
11
08
2022
accepted:
10
01
2023
medline:
4
4
2023
entrez:
3
4
2023
pubmed:
4
4
2023
Statut:
epublish
Résumé
The aim of the present study was to analyze incidence, histopathological features and clinical outcomes of patients undergoing radical cystoprostatectomy (RCP) for bladder cancer, in which incidental prostate cancer (PCa) was found. How these types of cancer impacted the patients' management and whether prostate-sparing cystectomy could be an option for these patients was determined. The current study retrospectively analyzed the data of a cohort of patients from 'Umberto I' Hospital of Nocera Inferiore who underwent RCP for bladder transitional cell carcinoma. Patients with a preoperative diagnosis or clinical suspicion of PCa were excluded. Patients affected by incidental PCa in the RCP specimens were identified, and then their demographic, histopathological and clinical outcome data were collected. Overall, it was revealed that of the 303 patients undergoing RCP for bladder cancer, 69 (22.7%) had incidental PCa, with a median age of 71.6 (age range, 54-89 years). In total, 23 (33.33%) of the 69 patients with incidental PCa were considered to have clinically significant prostate disease. In conclusion, it was relatively common to identify incidental PCa in RCP specimens but no preoperative predictive factors were identified that were able to determine 'non-aggressive' PCa status. Therefore, the present results demonstrate the need for a careful and complete prostate removal during RCP. Nevertheless, since organ-sparing surgeries are widely performed in young population, due to the impossibility of predicting aggressive prostate cancer, these patients require close monitoring through lifelong PSA surveillance, particularly focusing on the possible relapse of PCa after RCP.
Identifiants
pubmed: 37006882
doi: 10.3892/etm.2023.11872
pii: ETM-25-4-11872
pmc: PMC10061260
doi:
Types de publication
Journal Article
Langues
eng
Pagination
173Informations de copyright
Copyright: © Baio et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Eur Urol. 2007 Sep;52(3):648-57
pubmed: 17600614
BJU Int. 2007 Mar;99(3):554-8
pubmed: 17407514
Scand J Urol Nephrol. 1999 Feb;33(1):27-30
pubmed: 10100360
Eur Urol. 2008 Feb;53(2):370-5
pubmed: 17689003
Urology. 1991 Mar;37(3):202-6
pubmed: 2000674
Cancer. 1988 Jan 15;61(2):396-401
pubmed: 3334974
J Urol. 1997 Jan;157(1):65-7
pubmed: 8976217
Virchows Arch. 2006 Feb;448(2):111-8
pubmed: 16328356
J Urol. 2000 Jun;163(6):1734-8
pubmed: 10799171
J Urol. 2004 Feb;171(2 Pt 1):646-51
pubmed: 14713778
J Urol. 2005 Apr;173(4):1314-7
pubmed: 15758788
J Clin Oncol. 2001 Feb 1;19(3):666-75
pubmed: 11157016
Jpn J Clin Oncol. 1985 Apr;15 Suppl 1:201-10
pubmed: 4009982
Ann N Y Acad Sci. 1964 Apr 2;114:896-921
pubmed: 14131934
Cancer. 1987 Jan 15;59(2):380-4
pubmed: 3802024
Urology. 2004 Feb;63(2):268-72
pubmed: 14972469
Eur Urol. 2014 Apr;65(4):778-92
pubmed: 24373477
Eur Urol. 1996;30(3):322-6
pubmed: 8931964
Eur Urol. 2011 Aug;60(2):291-303
pubmed: 21601982
Natl Cancer Inst Monogr. 1985 Dec;68:149-59
pubmed: 4088296
J Natl Cancer Inst. 1995 Feb 1;87(3):175-82
pubmed: 7707404
J Urol. 1969 Apr;101(4):602-7
pubmed: 5776047
CA Cancer J Clin. 1995 Jan-Feb;45(1):8-30
pubmed: 7528632
J Urol. 1989 May;141(5):1091-4; discussion 1093-4
pubmed: 2785219
Eur Urol. 2008 Jan;53(1):68-80
pubmed: 17920184
Urol Int. 2005;75(3):213-6
pubmed: 16215307
Cancer. 1989 Jan 15;63(2):381-5
pubmed: 2910445
BJU Int. 2009 Apr;103(8):1058-63
pubmed: 19076141
BJU Int. 2010 Feb;105(4):468-71
pubmed: 20102366